Virological and clinical outcomes in outpatients treated with baloxavir or oseltamivir: A Japanese multicenter study in the 2019–2020 influenza seasonYong Chong, Hideyuki Ikematsu, Naoki Kawai et al.|Antiviral Research|2021Cited by 16
Virological and clinical outcomes in outpatients treated with baloxavir or neuraminidase inhibitors for A(H3N2) influenza: A multicenter study of the 2022–2023 seasonTakeyuki Goto, Hideyuki Ikematsu, Naoki Kawai et al.|Antiviral Research|2024Cited by 9
Susceptibility of epidemic viruses to neuraminidase inhibitors and treatment-emergent resistance in the Japanese 2019-20 influenza seasonNaoki Tani, Hideyuki Ikematsu, Naoki Kawai et al.|Journal of Infection|2021Cited by 8
Virological and Clinical Outcomes of Influenza Outpatients Treated With Baloxavir, Oseltamivir, or Laninamivir in the 2023–2024 SeasonTakeyuki Goto, Hideyuki Ikematsu, Yoshio Takasaki et al.|Influenza and Other Respiratory Viruses|2024Cited by 5
In vitro neuraminidase inhibitory concentrations (IC50) of four neuraminidase inhibitors in the Japanese 2023–24 season: Comparison with the 2010–11 to 2022–23 seasonsTakeyuki Goto, Hideyuki Ikematsu, Naoki Kawai et al.|Journal of Infection and Chemotherapy|2024Cited by 4